会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • SYSTEM AND METHOD FOR MONITORING DIASTOLIC FUNCTION USING AN IMPLANTABLE MEDICAL DEVICE
    • 使用可植入医疗装置监测脱脂功能的系统和方法
    • US20120330371A1
    • 2012-12-27
    • US13601569
    • 2012-08-31
    • Allen KeelSteve KohTaraneh Ghaffari Farazi
    • Allen KeelSteve KohTaraneh Ghaffari Farazi
    • A61N1/365
    • A61N1/3702A61N1/3627A61N1/36507A61N1/368A61N1/3712
    • Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.
    • 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中,可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地,T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中,基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。
    • 3. 发明申请
    • System and Method for ATP Treatment Utilizing Multi-Electrode Left Ventricular Lead
    • 使用多电极左心室铅的ATP治疗的系统和方法
    • US20120191154A1
    • 2012-07-26
    • US13012574
    • 2011-01-24
    • Kyungmoo RyuStuart RosenbergAllen KeelTaraneh Ghaffari FaraziRichard WilliamsonMark Carlson
    • Kyungmoo RyuStuart RosenbergAllen KeelTaraneh Ghaffari FaraziRichard WilliamsonMark Carlson
    • A61N1/365
    • A61N1/36521A61N1/3622A61N1/3684A61N1/3686A61N1/3962
    • An implantable medical device includes a lead configured to be located proximate to the left ventricle (LV) of the heart, the lead including multiple LV electrodes to sense cardiac activity at multiple LV sensing sites. The a detection module to detect an arrhythmia that represents at least one of a tachycardia and fibrillation based at least in part on the cardiac activity sensed at the multiple LV sensing sites. The ATP therapy module to identify at least one of an ATP configuration or an ATP therapy site based on the cardiac sensed activity at the LV sensing sites, the ATP therapy module to control delivery of antitachycardia pacing (ATP) therapy at the ATP therapy site. The ATP therapy module delivers a stimulus to electrodes at one or more of an LV site, right ventricular (RV) site and right atrial (RA) site, the detection module to sense evoked responses at the LV sensing sites, the ATP therapy module to designate the ATP therapy site to include at least the LV sensing site with a shortest activation time relative to the one or more LV site, RV site and RA site where the stimulus is delivered.
    • 可植入医疗装置包括被配置为位于心脏左心室(LV)附近的引线,该引线包括多个LV电极以感测多个LV感测部位的心脏活动。 该检测模块至少部分地基于在多个LV感测位点处感测到的心脏活动来检测代表心动过速和颤动中的至少一种的心律失常。 ATP治疗模块基于LV感测位点处的心脏感测活动来鉴定ATP配置或ATP治疗部位中的至少一个,ATP治疗模块用于控制ATP治疗部位的抗心动过速起搏(ATP)治疗的递送。 ATP治疗模块向LV位点,右心室(RV)位点和右心房(RA)位点的一个或多个处的电极施加刺激,检测模块用于感测LV感测位点处的诱发反应,ATP治疗模块 指定ATP治疗部位至少包括相对于传递刺激物的一个或多个LV部位,RV部位和RA部位具有最短激活时间的LV感测部位。
    • 10. 发明授权
    • System and method for monitoring diastolic function using an implantable medical device
    • 使用可植入医疗装置监测舒张功能的系统和方法
    • US08874213B2
    • 2014-10-28
    • US13601569
    • 2012-08-31
    • Allen KeelSteve KohTaraneh Ghaffari Farazi
    • Allen KeelSteve KohTaraneh Ghaffari Farazi
    • A61N1/362A61N1/37A61N1/368A61N1/365
    • A61N1/3702A61N1/3627A61N1/36507A61N1/368A61N1/3712
    • Diastolic function is monitored within a patient using a pacemaker or other implantable medical device. In one example, the implantable device uses morphological parameters derived from the T-wave evoked response waveform as proxies for ventricular relaxation rate and ventricular compliance. In particular, the magnitude of the peak of the T-wave evoked response is employed as a proxy for ventricular compliance. The maximum slew rate of the T-wave evoked response following its peak is employed as a proxy for ventricular relaxation. A metric is derived from these proxy values to represent diastolic function. The metric is tracked over time to evaluate changes in diastolic function. In other examples, specific values for ventricular compliance and ventricular relaxation are derived for the patient based on the T-wave evoked response parameters.
    • 使用起搏器或其他可植入医疗器械在患者体内监测舒张功能。 在一个示例中,可植入装置使用从T波诱发反应波形导出的形态参数作为心室松弛率和心室顺应性的代理。 特别地,T波诱发反应的峰值的大小被用作心室顺应性的代表。 其峰值后的T波诱发反应的最大压摆率被用作心室松弛的代用品。 来自这些代理值的度量来表示舒张功能。 随着时间的推移跟踪度量以评估舒张功能的变化。 在其他实例中,基于T波诱发反应参数为患者导出心室顺应性和心室松弛的具体值。